DCM
REGN icon

Decatur Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Decatur Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,677
Closed -$2.81M – 53
2024
Q3 		$2.81M Buy
2,677
+3
+0.1% +$3.34K 1.3% 23
2024
Q2 		$2.81M Buy
2,674
+69
+3% +$66.9K 1.36% 21
2024
Q1 		$2.51M Sell
2,605
-25
-1% -$23.8K 1.36% 21
2023
Q4 		$2.31M Buy
2,630
+191
+8% +$157K 1.38% 21
2023
Q3 		$2.01M Hold
2,439
– – 1.45% 19
2023
Q2 		$1.75M Sell
2,439
-34
-1% -$26.2K 1.2% 29
2023
Q1 		$2.03M Sell
2,473
-473
-16% -$357K 1.53% 18
2022
Q4 		$2.13M Hold
2,946
– – 1.53% 21
2022
Q3 		$2.03M Hold
2,946
– – 1.54% 16
2022
Q2 		$1.74M Hold
2,946
– – 1.29% 28
2022
Q1 		$2.06M Buy
2,946
+286
+11% +$181K 1.2% 25
2021
Q4 		$1.68M Buy
+2,660
New +$1.64M 1% 34
2017
Q2 		– Sell
-1,217
Closed -$472K – 72
2017
Q1 		$472K Buy
+1,217
New +$451K 0.09% 56
2015
Q4 		– Sell
-1,025
Closed -$477K – 105
2015
Q3 		$477K Buy
+1,025
New +$550K 0.07% 97
2015
Q2 		– Sell
-7,425
Closed -$3.35M – 102
2015
Q1 		$3.35M Hold
7,425
– – 0.42% 56
2014
Q4 		$3.05M Sell
7,425
-8,325
-53% -$3.27M 0.41% 55
2014
Q3 		$5.68M Buy
15,750
+4,775
+44% +$1.6M 0.95% 37
2014
Q2 		$3.1M Buy
+10,975
New +$3.25M 0.58% 70
2014
Q1 		– Sell
-12,660
Closed -$3.48M – 99
2013
Q4 		$3.48M Sell
12,660
-525
-4% -$151K 0.67% 62
2013
Q3 		$4.13M Sell
13,185
-13,000
-50% -$3.42M 0.87% 55
2013
Q2 		$5.89M Buy
+26,185
New +$6.1M 2.04% 15

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Decatur Capital Management's REGN Position: Q4 2024 in Review

Decatur Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 2,677 shares — an estimated $2.81M sold.

Decatur Capital Management first reported a position in REGN in Q2 2013 and held it in 21 quarters. The position peaked at $5.89M in Q2 2013. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Decatur Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Decatur Capital Management sold 2,677 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $2.81M.
  • Decatur Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Decatur Capital Management's Regeneron Pharmaceuticals position peaked at $5.89M in Q2 2013.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Decatur Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.